Filing Details
- Accession Number:
- 0001209191-14-012245
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2014-02-20 14:59:13
- Reporting Period:
- 2014-02-18
- Filing Date:
- 2014-02-20
- Accepted Time:
- 2014-02-20 14:59:13
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1419600 | Flexion Therapeutics Inc | FLXN | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1574139 | Sas Partners Sofinnova | 16-18 Rue De 4 Septembre Paris I0 75002 | No | No | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2014-02-18 | 1,614,382 | $0.00 | 1,614,382 | No | 4 | C | Direct | |
Common Stock | Acquisiton | 2014-02-18 | 260,340 | $0.00 | 1,874,722 | No | 4 | C | Direct | |
Common Stock | Acquisiton | 2014-02-18 | 230,769 | $13.00 | 2,105,491 | No | 4 | P | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | C | Direct | |
No | 4 | C | Direct | |
No | 4 | P | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Series A Preferred Stock | Disposition | 2014-02-18 | 13,124,932 | $0.00 | 1,614,382 | $0.00 |
Common Stock | Series B Preferred Stock | Disposition | 2014-02-18 | 2,116,562 | $0.00 | 260,340 | $0.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | No | 4 | C | Direct | ||
0 | No | 4 | C | Direct |
Footnotes
- Every 8.13 shares of Series A Preferred Stock automatically converted into 1 share of Common Stock without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.
- Every 8.13 shares of Series B Preferred Stock automatically converted into 1 share of Common Stock without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.
- The shares were purchased at the Issuer's initial public offering.